Radcliffe Capital Management’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Radcliffe Capital Management’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-66,566	Closed	-$672K	–	830
2022 Q4	$672K	Sell	66,566 -100	-0.2%	-$20	0.02%	752
2022 Q3	$661K	Hold	66,666	–	–	0.02%	1023
2022 Q2	$653K	Hold	66,666	–	–	0.02%	1078
2022 Q1	$651K	Hold	66,666	–	–	0.01%	1082
2021 Q4	$647K	Hold	66,666	–	–	0.02%	946
2021 Q3	$649K	Hold	66,666	–	–	0.02%	800
2021 Q2	$647K	Buy	+66,666	New	+$62K	0.02%	819

Radcliffe Capital Management's EBACW Position: Q1 2023 in Review

Radcliffe Capital Management sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 66,566 shares — an estimated $672K sold.

Radcliffe Capital Management first reported a position in EBACW in Q2 2021 and held it in 7 quarters. The position peaked at $672K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

Radcliffe Capital Management reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
Radcliffe Capital Management sold 66,566 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $672K.
Radcliffe Capital Management first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2021 and held it in 7 quarters.
Radcliffe Capital Management's European Biotech Acquisition Corp. Warrant position peaked at $672K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on Radcliffe Capital Management's 13F filing for Q1 2023, filed 15 May 2023.